Bizarre Patents
System for magnetically attaching templeless eyewear to a person
A system of eyewear that eliminates the need for hinges on the frames of the eyewear.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8173396 | Methods for reducing gluconoylation of proteins The present invention relates to methods of preventing glyconoylation of polypeptides produced in micororganisms. ... | 05/08/2012 |
| 8129503 | Agents that bind a target in pulmonary tissue for targeting respiratory diseases Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for ad... | 03/06/2012 |
| 8084213 | Selection The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain. ... | 12/27/2011 |
| 8071731 | Humanised anti-MAG antibody or functional fragment thereof The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ... | 12/06/2011 |
| 8017115 | Therapeutical use of anti-myelin associated glycoprotein (MAG) antibodies A method of promoting oligodendrocyte survival in a human suffering from, or at risk of developing, stroke or other neurological diseases utilizes anti-MAG antibodies or functional fragments of such antibodies. ... | 09/13/2011 |
| 8003101 | Inflammatory mediator antagonists The present invention relates to methods of reducing cartilage degradation in a patient comprising administering to a patient in need thereof an effective amount of an antibody antagonist to the mature form of OSM. ... | 08/23/2011 |
| 7988964 | NOGO-a neutralising immunoglobulin for treatment of neurological diseases The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the t... | 08/02/2011 |
| 7982005 | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided. ... | 07/19/2011 |
| 7939074 | Combination of an anti-EP-CAM antibody with a chemotherapeutic agent A combination of an anti-Ep-CAM antibody with a chemotherapeutic agent that is capable of arresting Ep-CAM antigen expressing cells in S or G2/M. ... | 05/10/2011 |
| 7846721 | GAS1 universal leader Disclosed is a polynucleotide molecule comprising a promoter operably linked to a nucleic acid sequence encoding a GAS1 secretion signal peptide, wherein said promoter is not a rhamnose promoter. ... | 12/07/2010 |
| 7858753 | Immunoglobulins The present invention concerns immunoglobulins, such as antibodies, which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and modulate the interaction between OSM and gp130. In typical embodiments, OSM is glycosylated. The invention also concerns... | 12/28/2010 |
| RE41974 | Method for culturing Chinese hamster ovary cells A biochemically defined culture medium for culturing engineered Chinese hamster ovary (CHO) cell lines, which is essentially free from protein, lipid and carbohydrate isolated from an animal source, having water, an osmolality regulator, a buffer, an energy source, ... | 11/30/2010 |
| 7807793 | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided. ... | 10/05/2010 |
| 7807788 | Chimeric and humanised monoclonal antibodies against Interleukin-13 The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction ... | 10/05/2010 |
| RE41595 | Antibody purification This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecule proteins. ... | 08/31/2010 |
| 7780964 | Immunoglobulins which bind NOGO The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ... | 08/24/2010 |
| RE41555 | Antibody purification This invention relates to the application of hydrophobic interaction chromatography combination chromatography to the purification of antibody molecular proteins. ... | 08/24/2010 |
| 7736639 | Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed. ... | 06/15/2010 |
| 7696320 | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cance... | 04/13/2010 |
| 7662633 | Method of screening for inhibitors of osteopontin Amino acids 136 to 142 and amino acids 162 to 168 of human osteopontin constitute two sites at which osteopontin interacts with α4 integrins. Products capable of disrupting those interactions are useful in therapy, particularly in the treatment of inflammatory dise... | 02/16/2010 |
| 7655425 | Uses of a chemokine receptor able to bind to MCP-1, MIP-1α and/or RANTES A chemokine receptor binds to MCP-1, MIP-1α and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1α and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated... | 02/02/2010 |
| 7622302 | Process for improving the manufacture of clavams e.g. clavulanic acid New processes for improving the manufacture of clavams e.g. clavulanic acid. Novel DNA sequences and new microorganisms capable of producing increased amounts of clavulanic acid are also disclosed. ... | 11/24/2009 |
| RE40988 | Ligands of the neuropeptide receptor HFGAN72 Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, method... | 11/17/2009 |
| 7612183 | Humanised anti-mag antibody or functional fragment thereof The present invention relates to altered antibodies to myelin associated glycoprotein (MAG), pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. ... | 11/03/2009 |
| 7595039 | Methods of healing wounds by administering human IL-18 The present invention relates generally to the use of human IL-18, also known as interferon-γ-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury. ... | 09/29/2009 |
| 7557191 | Sialoadhesin factor-2 antibodies Monoclonal antibodies have been generated that bind to human sialoadhesion factor-2. These antibodies are useful as diagnostic and therapeutic reagents. ... | 07/07/2009 |
| 7507834 | Substituted anilinopyrazoles The present invention relates to anilinopyrazole derivatives, methods for the preparation of such anilinopyrazoles, and use of such anilinopyrazoles in the treatment of certain diseases or conditions. In particular, the present invention relates to a nilinopyrazole ... | 03/24/2009 |
| 7501512 | Chemical compounds This invention relates to newly identified inhibitors of kinases for treating various disorders. ... | 03/10/2009 |
| 7132262 | Papilloma virus sequences The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections and the symptoms and diseases associated therewith. More particularly, the invention relates to polynucleotide sequences which encode... | 11/07/2006 |
| 7105316 | lactoferrin binding protein LbpB polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing LbpB polypeptides and polynucleotides in the design of protocols for the treatment of neisserial disea... | 09/12/2006 |
| 7087748 | Process A novel process for the removal of impurities from clavulanic acid using a selective adsorption material, in particular a molecularly imprinted polymer. Novel selective adsorption materials suitable for the process, and a process for the preparation of such selectiv... | 08/08/2006 |
| 7045329 | Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy The enzyme Lp-PLA2 in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme. ... | 05/16/2006 |
| 6870030 | ASP2 ASP2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP2 polypeptides and polynucleotides in the design of protocols for the treatment of Alzheimer's Dise... | 03/22/2005 |
| 6432678 | Macaca cynomolgus IL 18 Macaca cynomolgus IL18 polypeptides and polynucleotides and method for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds which either agonize or antagonize Macaca cynomolgus IL18. S... | 08/13/2002 |
| 6433156 | Polynucleotide and polypeptide sequence of rabbit G-protein alpha 16 Rabbit G alpha 16 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing rabbit G alpha 16 polypeptides and polynucleotides in screening of antagonists... | 08/13/2002 |
| 6388055 | Mouse CC-CKR5 receptor polypeptide Mouse CC-CKR5 polypeptides and DNA (RNA) encoding such mouse CC-CKR5 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such mouse CC-CKR5 in the development of gene knockout mi... | 05/14/2002 |
| 6376214 | DNA encoding a novel homolog of CSBP/p38 MAP kinase p38beta2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing p38beta2 polypeptides and polynucleotides in the design of protocols for the treatment ... | 04/23/2002 |
| 6368823 | Kv potassium channel polypeptides and polynucleotides hKv4.3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hKv4.3 polypeptides and polynucleotides in the design of protocols for the treatment of c... | 04/09/2002 |
| 6365715 | Human cardiac/brain tolloid-like protein HC/BTLP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hC/BTLP polypeptides and polynucleotides in the design of protocols for the treatment of... | 04/02/2002 |
| 6361975 | Mouse aspartic secretase-2(mASP-2) mASP-2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for screening for compounds that either agonize or antagonize mASP-2. Such compounds are expected to be... | 03/26/2002 |
